Archives: Speakers

An internationally experienced executive with Corporate and Entrepreneurial experience. A career across 6 different countries, including developing markets, in a range of business sectors, and an ability to deliver above expectation results.

For over 25 years Hilary has developed brands across the health, wellness, and beauty sectors. Hilary has now chosen to channel her innovative direction and creation into the CBD industry, which is not only a new venture but an intersection of all her prior experiences.

Glen joined Luxoft in 2021 from IBM. His work is focused on insurance analytics use cases, and supporting and guiding data science, engineering and sales colleagues in partnering with clients. Before moving to the technology sector, after serving in law enforcement Glen first entered the insurance industry in Australia. This was followed by roles in insurers operating in the UK and Europe, with exposure to other regions too. He has held four Executive Director positions and Senior Management roles, worked for some of the world’s largest businesses, prominent brands, a scale-up, not-for-profit organization, formed part of industry strategy and milestone initiatives and also as an independent consultant to insurance and wider clients. Glen is viewed by peers as a source of creativity, pragmatism and fresh/different thinking and perspectives. He possesses comprehensive knowledge of insurance and the supply chain, including the wide opportunities for change and modernization. In particular, he’s widely regarded as a specialist in mitigating insurance fraud through the full policy life cycle; point of quote, sale, mid-term adjustment and claim.

Mackenzie Clavin is a Behavioural Research Consultant at Swiss Re based in London. Her research focuses on matters of Fairness in Underwriting, Human Bias the application of AI, and Customer Behaviour. Prior to specialising in Behavioural Science, Mackenzie worked as a Management Consultant in Financial Services for PwC and EY. She has a Masters in Cognitive and Decision Science from UCL, as well as a Bachelors in Biochemistry and Management from Imperial College London

Chris is the CFO & co-founder of Arma Karma, with a demonstrated history of working in the financial services industry. Previously worked at Barclays Wealth Management and Bloomberg. ACSI qualified with an MSc from Durham Business School and a BSc from University of Essex.

Reakiro founder and Serial entrepreneur with proven International success records within the FMCG, Marketing, Entertainment and Distribution Industries working alongside some of the worlds largest Multinational companies.

Paul Gurney is a Managing Director at BMO Capital Markets in London, UK, leading BMO’s coverage of large institutional equity clients in Europe and Asia Pacific. Paul has 15 years of capital markets experience, researching companies, syndicating transactions, structuring deals, and providing value-added advice to institutional and corporate clients across multiple sectors. In early 2018, Bank of Montreal (BMO) became the first major bank to underwrite the cannabis sector, leading a US$175m equity financing for the world’s largest cannabis company, Canopy Growth. Paul has been closely involved in the sector in Europe ever since, helping raise US$153m for Tilray, the first ever NASDAQ listed cannabis company, and the third best performing IPO in the US in 2018. Paul spearheads BMO’s investment efforts for cannabis companies in Europe, and Australia, introducing investors to sector heavyweights like Aphria, Aurora, Canopy Growth and Tilray, while actively developing the next generation of pre-IPO cannabis companies. Paul’s early involvement in the sector has helped him develop a deep network of industry and client contacts, making him one of the thought leaders for the sector in Europe.

Catherine is UK Representative & Member of the Board of Advisors of the European Industrial Hemp Association. EIHA was formed 19 years ago and is the only pan-European membership organization in the industrial hemp sector. Our secretariat offices in Brussels and the UK representation protect and support our membership of 200+, primarily farmers, processors and manufacturers; representing the entire chain from seed to shelf. Our primary objective is to monitor EU/UK hemp related policies and to provide the decision makers with accurate and reliable information across different spheres of competencies. Currently we monitor the following policies: CAP reform, Hemp extracts/Novel Food regulation, THC limits in feed and food, Life Cycle Assessment of hemp materials, CO2 impacts, environmental concerns and cosmetics. In addition, EIHA formed the largest novel food consortium and pending a successful outcome, EIHA consortium member company’s products will be allowed to be marketed in the UK/EU with an exclusivity on the study that will last 5 years.

Mr Tamir is a cannabis entrepreneur with seven years of hands-on experience in multiple cannabis ventures and has vast experience in consulting for international cannabis projects. Mr Tamir began his career and built his reputation as a senior strategy consultant at Accenture. He is also the founder of Teva Nature, the leading vaporizer company in Israel.
Mr Tamir founded Kanabo Research in 2016 and since then has served as its CEO of the company. He has led the company to list on London Stock Exchange by way of RTO, formulating Kanabo Group, Plc as the first public medical cannabis company in the UK. His expertise includes biotechnology, new agriculture and agro-tech, and other breakthrough technologies in the dynamic field of Medical Cannabis.

Golan is leading the Univo Pharmceutical talented and experienced team. At Univo Pharmceutical we take pride in our work and strive for consistent excellence. Golan has over 20 years of senior managerial roles in the Israel Ministry of Defense and as an officer in the IDF Special Forces. Golan Implemented and managed large scale multi-million dollar projects for the Israel Government. ☘ Univo Pharmceutical – Our Goals is to grow high-quality cannabis, in particular, to develop new cannabis strains and produce a wide range of GMP grade cannabis-based products for distribution and export to international markets. ☘ Univo Pharmceutical- Using one of the largest *cannabis databases* we are able to cater to the individualized needs of our customers and match the specific multi-faceted cannabis strain best suited to their individual needs. ☘ Univo Pharmceutical- Innovative *scientific formulas* Provides wide range of cannabis-based products, which are developed using new and innovative *scientific formulas*.